These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 2554644)
1. Ocular anaphylaxis induced in the rat by topical application of compound 48/80. Dose response and time course study. Allansmith MR; Baird RS; Ross RN; Barney NP; Bloch KJ Acta Ophthalmol Suppl (1985); 1989; 192():145-53. PubMed ID: 2554644 [TBL] [Abstract][Full Text] [Related]
2. Response of rat conjunctival mast cells to multiple versus single applications of compound 48/80. Allansmith MR; Baird RS; Barney NP; Ross RN; Bloch KJ Ophthalmic Res; 1989; 21(5):392-400. PubMed ID: 2481251 [TBL] [Abstract][Full Text] [Related]
3. Time course of human conjunctival mast cell degranulation in response to compound 48/80. Udell IJ; Kenyon KR; Hanninen LA; Abelson MB Acta Ophthalmol Suppl (1985); 1989; 192():154-61. PubMed ID: 2554645 [TBL] [Abstract][Full Text] [Related]
4. Effect of multiple applications of compound 48/80 on mast cells of rat conjunctiva. Allansmith MR; Baird RS; Ross RN; Barney NP; Bloch KJ Acta Ophthalmol (Copenh); 1987 Aug; 65(4):406-12. PubMed ID: 3661142 [TBL] [Abstract][Full Text] [Related]
5. Morphologic evidence that compound 48/80-challenged rat eyelid mast cells differ in their states of maximal degranulation. Allansmith MR; Baird RS; Ross RN Ophthalmic Res; 1989; 21(3):206-15. PubMed ID: 2476697 [TBL] [Abstract][Full Text] [Related]
6. Dark-staining bodies in the conjunctival epithelium of rats after multiple topical challenges with compound 48/80. Allansmith MR; Baird RS; Ross RN Ann Ophthalmol; 1988 Jul; 20(7):264-6, 270. PubMed ID: 2460012 [TBL] [Abstract][Full Text] [Related]
7. Late-phase reaction in topically induced ocular anaphylaxis in the rat. Trocmé SD; Bonini S; Barney NP; Bloch KJ; Allansmith MR Curr Eye Res; 1988 May; 7(5):437-43. PubMed ID: 3136973 [TBL] [Abstract][Full Text] [Related]
8. Determination of the interval during which one application of compound 48/80 to the rat conjunctiva influences the response to a second application. Allansmith MR; Baird RS; Barney NP; Ross RN; Bloch KJ Ophthalmic Res; 1990; 22(3):137-43. PubMed ID: 1696708 [TBL] [Abstract][Full Text] [Related]
9. Penetrating the conjunctival barrier. The role of molecular weight. Kahn M; Barney NP; Briggs RM; Bloch KJ; Allansmith MR Invest Ophthalmol Vis Sci; 1990 Feb; 31(2):258-61. PubMed ID: 2303328 [TBL] [Abstract][Full Text] [Related]
17. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675 [TBL] [Abstract][Full Text] [Related]
18. Animal and human ocular surface response to a topical nonimmune mast-cell degranulating agent (compound 48/80). Udell IJ; Abelson MB Am J Ophthalmol; 1981 Feb; 91(2):226-30. PubMed ID: 6162389 [TBL] [Abstract][Full Text] [Related]